No Data
No Data
Buy Rating Affirmed for ProKidney on Rilparencel's Promising Efficacy in CKD Treatment
Maintaining Hold on ProKidney: Balancing Market Potential Against Clinical Uncertainties
ProKidney(PROK.US) Officer Sells US$70,386.2 in Common Stock
$ProKidney(PROK.US)$ Officer Weber Darin J. sold 17,238 shares of common stock on May 20, 2024 at an average price of $4.0832 for a total value of $70,386.2.Source: Announcement What is statement of c
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data From Phase 2 RMCL-002 Clinical Trial on May 28, 2024
WINSTON-SALEM, N.C., May 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic ki
Form 144 | ProKidney(PROK.US) Officer Proposes to Sell 279.6K in Common Stocks
SEC FILLINGS DISCLOSED/ May 20, $ProKidney(PROK.US)$ Officer DARIN J WEBER intends to sell 68,952 shares of its common stock on May 20, with a total market value of approximately $279.6K. DARIN J WE
ProKidney(PROK.US) 10% Shareholder Buys US$251.67K in Common Stock
$ProKidney(PROK.US)$ 10% Shareholder Control Empresarial de Capitales S.A. de C.V. purchased 177K shares of common stock on Mar 13, 14, 20, 22, 25, 2024 at an average price of $1.4218 for a total valu
No Data